Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth

Affiliations

Editorial

Douglas A Corley. Gastroenterology. 2019 Sep.

. 2019 Sep;157(3):604-607.

doi: 10.1053/j.gastro.2019.07.039. Epub 2019 Jul 30.

¹ Kaiser Permanente, Division of Research, Oakland, California. Electronic address: dcorley.gastro@gmail.com.

No abstract available

Comment in

Proton Pump Inhibitor Therapy and Fracture Risk: Discrepancy of Results Between Observational and Interventional Studies.
Sugiyama T. Sugiyama T. Gastroenterology. 2020 Mar;158(4):1174. doi: 10.1053/j.gastro.2019.09.054. Epub 2020 Jan 23. Gastroenterology. 2020. PMID: 31982411 No abstract available.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Moayyedi P, et al. Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29. Gastroenterology. 2019. PMID: 31152740 Clinical Trial.